Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | GRM8 | O00222 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6937040 | 1.00 | CYP1A2 (0.59) | CYP1A2CYP2D6CYP2C19ALDH1A1KDM4E | |
| SCHEMBL6868397 | 0.86 | CYP1A2 (0.61) | CYP1A2CYP2D6CYP2C19ALDH1A1KDM4E | |
| SCHEMBL1439841 | 0.84 | CYP1A2 (0.63) | CYP1A2CYP2D6CYP2C19ALDH1A1KDM4E | |
| SCHEMBL1554077 | 0.84 | CYP1A2 (0.63) | CYP1A2CYP2D6CYP2C19ALDH1A1KDM4E | |
| SCHEMBL1439844 | 0.84 | CYP1A2 (0.63) | CYP1A2CYP2D6CYP2C19ALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL7600257 | 0.82 | CYP1A2 (0.61) | CYP1A2CYP2D6CYP2C19ALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL15511514 | 0.82 | CYP1A2 (0.61) | CYP1A2CYP2D6CYP2C19ALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL7595427 | 0.82 | CYP1A2 (0.61) | CYP1A2CYP2D6CYP2C19ALDH1A1KDM4E | |
| SCHEMBL13115768 | 0.82 | CYP1A2 (0.61) | CYP1A2CYP2D6CYP2C19ALDH1A1KDM4E | |
| SCHEMBL701930 | 0.82 | CYP1A2 (0.61) | CYP1A2CYP2D6CYP2C19ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230091047-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-23 | — | — | US | disclosed |
| US-20220324865-A1 | SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-10-13 | — | — | US | disclosed |
| EP-3793559-A1 | SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2021-03-24 | — | — | EP | disclosed |
| CN-112469412-A | Substituted dihydropyrazolopyrazine carboxamide derivatives | 拜耳公司 | 2021-03-09 | — | — | CN | disclosed |
| US-20160083400-A1 | TRICYCLIC GUANIDINE DERIVATIVE | SUNOVION PHARMACEUTICALS INC (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160083400-A1 | TRICYCLIC GUANIDINE DERIVATIVE | SUNOVION PHARMACEUTICALS INC (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160083400-A1 | TRICYCLIC GUANIDINE DERIVATIVE | SUNOVION PHARMACEUTICALS INC (US) | 2016-03-24 | — | — | US | disclosed |
| EP-1487442-B1 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | MERCK SERONO SA (CH) | 2010-12-01 | — | — | EP | disclosed |
| CN-100484524-C | Thiazolidine carboxamide derivatives as modulators of the prostaglandin receptor | APPLIED RESEARCH SYSTEMS (CH) | 2009-05-06 | — | — | CN | disclosed |
| EP-1470138-B1 | MMP INHIBITORS | LEO PHARMA AS (DK) | 2006-01-18 | — | — | EP | disclosed |
| CN-1655780-A | Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor | APPLIED RESEARCH SYSTEMS (AN) | 2005-08-17 | — | — | CN | disclosed |
| EP-1470138-A1 | MMP INHIBITORS | Leo Pharma A/S (DK) | 2004-10-27 | — | — | EP | disclosed |
| US-6784169-B2 | METALLOPROTEASE INHIBITOR; ANTIINFLAMAMTORY AGENTS; RHEUMATIC DISORDERS; CARDIOVASCULAR DISORDERS; CONTROLLING CELL PROLIFERATION | LEO PHARMACETICAL PRODUCTS LTD. (DK) | 2004-08-31 | — | — | US | disclosed |
| US-20030191092-A1 | MMP inhibitors | CHRISTENSEN METTE KNAK (DK) | 2003-10-09 | — | — | US | disclosed |
| WO-2003059921-A1 | MMP INHIBITORS | LEO PHARMA A/S (DK) | 2003-07-24 | — | — | WO | disclosed |
| EP-0918059-B1 | Substituted imidazoline derivatives, their preparation, their use, and pharmaceutical compositions containing them | AVENTIS PHARMA GMBH (DE) | 2003-06-25 | — | — | EP | disclosed |
| US-6521654-B2 | For therapy and prophylaxis of rheumatoid arthritis, or of allergic disorders, asthma, inflammation; inhibitors of the adhesion and migration of leucocytes and/or antagonists of adhesion receptor VLA-4 belonging to the integrins group | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-02-18 | — | — | US | disclosed |
| US-20020143043-A1 | Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations including them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-10-03 | — | — | US | disclosed |
| US-6331552-B1 | THERAPY AND PROPHYLAXIS OF INFLAMMATORY DISORDERS, FOR EXAMPLE OF RHEUMATOID ARTHRITIS, OR OF ALLERGIC DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-12-18 | — | — | US | disclosed |
| EP-0918059-A1 | Substituted imidazoline derivatives, their preparation, their use, and pharmaceutical compositions containing them | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324865-A1 | SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES | QDPR, SIRT5, PDXK | CYP1A2 191/4885CYP2D6 173/4885CYP2C19 139/4885 |
| US-20020143043-A1 | Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations including them | VCAM1, ITGA1, ITGA4 | CYP1A2 1137/4885CYP2D6 1024/4885CYP2C19 1152/4885 |
| US-20230091047-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | HAVCR2, HCCS, TYMP | CYP1A2 338/4885CYP2D6 212/4885CYP2C19 545/4885 |
| US-20030191092-A1 | MMP inhibitors | MMP11, MMP1, MMP13 | CYP1A2 1285/4885CYP2D6 421/4885CYP2C19 1214/4885 |
| US-20160083400-A1 | TRICYCLIC GUANIDINE DERIVATIVE | PDE3A, PDE2A, PDE5A | CYP1A2 659/4885CYP2D6 1483/4885CYP2C19 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.